There are 3161 resources available
1296P - A phase II study to evaluate the efficacy and safety of BB-1701 in advanced or metastatic NSCLC patients with HER2 mutation/amplification
Presenter: Caicun Zhou
Session: Poster session 05
1297P - A phase II study of pyrotinib combined with apatinib in first-line treatment of advanced non-small cell lung cancer patients with primary HER-2 mutations/amplification
Presenter: Wenxin Jiang
Session: Poster session 05
1299P - First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer
Presenter: Alessandro Di Federico
Session: Poster session 05
1300P - Treatment sequences in BRAF-V600-mutant non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy
Presenter: Marcel Wiesweg
Session: Poster session 05
1301P - BRAF-mutant metastatic non-small cell lung cancer: Real-world data from the Italian biomarker ATLAS database
Presenter: Alessandro Russo
Session: Poster session 05
1302P - MET×MET bispecific antibody davutamig (REGN5093) for MET-altered advanced non-small cell lung cancer (aNSCLC): Update from a first-in-human (FIH) study
Presenter: Byoung Chul Cho
Session: Poster session 05
1303P - METPRO: Evaluating prognostic value of c-Met protein overexpression and concurrent biomarker presence
Presenter: Xiuning Le
Session: Poster session 05
1304P - Investigator-initiated study of crizotinib in patients with MET activated advanced stage non-small cell lung cancer: A Canadian experience
Presenter: Abdulrahman Alghabban
Session: Poster session 05
1305P - Sotorasib long-term clinical outcomes in pretreated KRAS G12C-mutated advanced NSCLC: Pooled analysis from the CodeBreaK clinical trials
Presenter: Ferdinandos Skoulidis
Session: Poster session 05